Sweden's BioGaia Q2 sales rises on segment growth
Sweden's BioGaia Q2 sales rises on segment growth
Overview
Sweden probiotic products maker's Q2 net sales rose 9% yr/yr including currency effects
Adjusted EPS for Q2 rose to SEK 1.02 from SEK 0.87 yr/yr
Growth driven by both Pediatrics and Adult Health segments; APAC sales declined
Outlook
BioGaia says it remains focused on sustainable growth and profitability through innovation
Company sees continued variability in APAC sales due to order timing fluctuations
BioGaia plans to share more on strategy and growth drivers at its Capital Markets Day in December
Result Drivers
PRODUCT PORTFOLIO - Growth in Q2 was primarily driven by BioGaia Protectis Drops, Prodentis, Protectis chewables and Gastrus Pure Action capsules, according to CEO Theresa Agnew
REGIONAL PERFORMANCE - EMEA and Americas regions delivered strong sales growth, while APAC sales declined due to lower sales in China and South Korea and order timing variability
OPERATING EXPENSES - Operating expenses, excluding items affecting comparability, decreased by 4%, supporting higher operating margins
Company press release: ID:nWkrb8fK4m
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Slight Miss* | SEK 440.90 mln | SEK 443.60 mln (2 Analysts) |
Q2 Adjusted EPS |
| SEK 1.02 |
|
Q2 Net Income |
| SEK 103.20 mln |
|
Q2 EBIT | Slight Miss* | SEK 132.10 mln | SEK 132.70 mln (2 Analysts) |
Q2 EBIT Margin |
| 30.00% |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Biogaia AB is SEK162.50, about 40.1% above its July 16 closing price of SEK116.00
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 28 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)